Feb 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Reports Q4 revenue $7.6B, consensus $7.15B. “Gilead (GILD) delivered another exceptionally strong full year and fourth quarter, with growth in our base business product sales of 8% for 2024 and ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on GILD: Gilead Sciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

Gilead Sciences, a leader in HIV drugs, faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033, making diversification crucial. The current stock price at $95+ implies 5 ...

The company has grown since then, and its logo design features a simple yet stylish red HH on a white background. This versatile fashion logo looks great on men’s and women’s clothing. Today, they are ...

(UBER), Comcast Corp. (CMCSA) and Gilead Sciences, Inc. (GILD), as well as a micro-cap stock Onfolio Holdings, Inc. (ONFO). The Zacks microcap research is unique as our research content on these ...